--- canonical_name: 3HAA alternate_names: 3-Hydroxyanthranilic Acid, 3-HAA, 3HANA, 2-Amino-3-hydroxybenzoic acid canonical_topic: 3HAA for Health & Longevity short_topic_lc: 3haa creation_date: 2026-0625-1328 creator_ai_fullname: Opus 4.8 ep_keywords: Kynurenine Pathway Metabolites, Tryptophan Catabolites, Tryptophan Metabolites --- # 3HAA for Health & Longevity
Evidence Review created on 06/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** 3-Hydroxyanthranilic Acid, 3-HAA, 3HANA, 2-Amino-3-hydroxybenzoic acid ## Motivation A small molecule the body makes when it breaks down a building block of dietary protein, 3HAA (3-hydroxyanthranilic acid) was for decades viewed as a fleeting, throwaway step on the way to making cellular energy carriers. Recent work has reframed it as a substance that, when its levels are raised, appears to switch on the cell's own defenses against damage. Interest grew after laboratory animals lived markedly longer and stayed healthier into old age when 3HAA was allowed to accumulate, either by blocking the enzyme that destroys it or by adding it to the diet. A separate line of work found that the same molecule rises in the blood of middle-aged people after months of regular exercise, hinting it may be one of the chemical messengers behind some benefits of physical activity. This review examines what is known about 3HAA as a potential health and longevity intervention. It surveys the proposed biological actions, the strength of the evidence for benefits and risks, the practical realities of supplementation, and the open questions that current research is still working to answer. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level resources that give an accessible overview of 3HAA and its emerging role in aging biology. * [On the benefits of the tryptophan metabolite 3-hydroxyanthranilic acid in Caenorhabditis elegans and mouse aging](https://pubmed.ncbi.nlm.nih.gov/38097593/) - Dang et al., 2023 The foundational primary-research report showing that raising 3HAA extends lifespan by roughly 30% in worms and that long-lived effects carry into mice; the most complete single source on the longevity hypothesis. * [3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity](https://pubmed.ncbi.nlm.nih.gov/38786006/) - Hull et al., 2024 An accessible primary study extending the 3HAA story to neurodegeneration models, showing delayed paralysis in worms engineered to mimic Alzheimer's and Huntington's disease. * [Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities](https://pubmed.ncbi.nlm.nih.gov/39304346/) - Pocivavsek et al., 2024 A narrative review that situates 3HAA within the broader kynurenine pathway, explaining how its parent and neighboring metabolites influence the brain and why the pathway's enzymes are drug targets. * [Unlocking Longevity: The Role of 3-Hydroxyanthranilic Acid (3HAA) in Aging](https://www.sunybiotech.com/news-show-196.html) - SunyBiotech A plain-language overview written for a general audience that summarizes the key animal findings and the proposed oxidative-stress mechanism without requiring a research background. * [The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice](https://pubmed.ncbi.nlm.nih.gov/22711758/) - Zhang et al., 2012 An earlier primary study, predating the longevity work, demonstrating that 3HAA reduces plaque and blood lipids in mice, providing context for its cardiovascular and anti-inflammatory actions. _Note: No dedicated, by-name content on 3HAA was found from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine). 3HAA is an early-stage research metabolite rather than a mainstream supplement, so the list above draws on the strongest available primary research, a narrative review, and one accessible lay summary instead._ ## Grokipedia [3-Hydroxyanthranilic acid](https://grokipedia.com/page/3_hydroxyanthranilic_acid) The dedicated Grokipedia entry summarizes the compound's chemistry, its place in the kynurenine pathway, and its biological roles, serving as a concise structured reference. ## Examine No Examine.com article exists for 3HAA. Examine.com focuses on consumer dietary supplements and ingredients with marketed products and human trial data; 3HAA is a research-grade endogenous metabolite without a consumer supplement profile, so it is not covered. ## ConsumerLab No ConsumerLab.com article exists for 3HAA. ConsumerLab tests and reviews commercially marketed supplement products for quality and label accuracy; 3HAA is not sold as a finished consumer supplement, so no product review is available. ## Systematic Reviews The following systematic reviews and meta-analyses address 3HAA within the broader kynurenine pathway, as no review focuses on 3HAA supplementation alone. * [Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/36263032/) - Fathi et al., 2022 Pooled data from 30 studies comparing kynurenine pathway metabolites, including 3HAA, between neurodegenerative-disease patients and controls; useful for understanding how 3HAA levels shift in age-associated brain disease. * [A systematic review and meta-analysis of the kynurenine pathway of tryptophan metabolism in rheumatic diseases](https://pubmed.ncbi.nlm.nih.gov/37936702/) - Mangoni & Zinellu, 2023 A meta-analysis of 24 studies that, notably, found no significant difference in 3HAA between patients with rheumatic disease and controls, helping to delineate which conditions 3HAA does and does not track with. ## Mechanism of Action 3HAA is a downstream product of the kynurenine pathway (KP), the main route by which the body breaks down the amino acid tryptophan to ultimately make NAD⁺ (nicotinamide adenine dinucleotide, a coenzyme essential for cellular energy and repair). It is produced from 3-hydroxykynurenine by the enzyme kynureninase and is normally destroyed within seconds by the enzyme HAAO (3-hydroxyanthranilic acid 3,4-dioxygenase), which converts it toward quinolinic acid. The leading explanation for 3HAA's benefits is an oxidative-stress-response (hormetic) mechanism. When 3HAA accumulates, it activates the SKN-1 transcription factor in worms — the equivalent of NRF2 (a master regulator that switches on the cell's antioxidant and detoxification genes) in mammals. This raises the cell's defenses against reactive oxygen species (unstable molecules that damage proteins, lipids, and DNA). Paradoxically, 3HAA can itself directly break down hydrogen peroxide, acting as a free-radical scavenger; the modest stress it imposes is thought to "train" the cell's protective systems. Alterations in iron homeostasis and improved protein homeostasis (the cell's ability to keep proteins correctly folded) have also been proposed as contributors. A competing mechanistic view treats 3HAA as a potential pro-oxidant and toxin rather than a protector. Under certain conditions — particularly in the presence of copper or transition metals — 3HAA generates superoxide and hydrogen peroxide and can enhance metal-driven toxicity, and it sits one enzymatic step upstream of quinolinic acid, an excitotoxin (a molecule that can overstimulate and damage nerve cells). Whether 3HAA is net-protective or net-harmful appears to depend heavily on dose, tissue, and local redox conditions, and both views are supported by experimental data. As 3HAA is a small endogenous molecule rather than a conventional drug, classical pharmacological properties are not well characterized in humans. In its role as the HAAO substrate it has an extremely short biological half-life — on the order of seconds to minutes — because HAAO rapidly clears it; it is water-soluble, distributes through plasma and tissues, and is metabolized chiefly by HAAO toward quinolinic acid and NAD⁺ synthesis. No cytochrome P450 (CYP, the liver's main drug-metabolizing enzyme family) pathway is a primary route for its clearance. ## Historical Context & Evolution 3HAA was originally of interest purely as a biochemical waypoint — a transient intermediate identified in the mid-twentieth century during the mapping of how the body converts tryptophan into NAD⁺. For most of its history it had no "intended use"; it was simply a metabolite measured by biochemists studying the kynurenine pathway, with no therapeutic ambitions attached. The reasons it came to be considered for health optimization emerged in two waves. First, in the 2000s and 2010s, researchers studying immune regulation and cardiovascular disease found that 3HAA had anti-inflammatory actions in animal models of autoimmune disease and atherosclerosis, where it lowered blood lipids and reduced arterial plaque. Second, and more decisively, aging researchers screening kynurenine pathway genes discovered that blocking the enzyme that destroys 3HAA extended lifespan in invertebrates — reframing the molecule from metabolic byproduct to candidate longevity agent. The scientific opinion on 3HAA has genuinely shifted and remains unsettled rather than settled. Early literature emphasized its potential toxicity and pro-oxidant chemistry, especially in the brain; newer work emphasizes hormetic, protective, and lifespan-extending effects. What changed was the introduction of genetic tools to raise 3HAA at physiological levels (rather than flooding cells with high concentrations) and longevity assays in worms and mice. Both bodies of evidence stand, and the field has not converged on a single verdict; 3HAA is best characterized as a metabolite whose net effect is context-dependent and actively debated. ## Expected Benefits A dedicated search of primary research and expert sources was performed to assemble the benefit profile below. ### High 🟩 🟩 🟩 (No benefits qualify for the High evidence level. All current evidence for 3HAA is preclinical or observational; none rests on human clinical trials.) ### Medium 🟩 🟩 (No benefits qualify for the Medium evidence level.) ### Low 🟩 #### Lifespan and Healthspan Extension In *Caenorhabditis elegans*, knocking down the HAAO enzyme (which raises physiological 3HAA) extends lifespan by approximately 30% and delays age-associated declines in movement and vigor; in pilot mouse studies, female HAAO-knockout mice and aging male mice fed 3HAA-supplemented diets were also longer-lived. The proposed mechanism is activation of the SKN-1/NRF2 oxidative-stress response and improved protein homeostasis with age. The evidence basis is robust invertebrate work plus small, preliminary mouse cohorts; no human lifespan data exist, and the mouse results were described by the authors as pilot-scale. **Magnitude:** ~30% median lifespan extension in *C. elegans*; mouse effects reported as positive but pilot-scale and not precisely quantified. #### Reduced Atherosclerosis and Improved Blood Lipids In atherosclerosis-prone mice, eight weeks of 3HAA treatment reduced arterial lesion size, lowered plasma cholesterol and triglycerides, and blunted local and systemic inflammation, partly by reducing macrophage uptake of oxidized LDL (low-density lipoprotein, the "bad" cholesterol carrier; its uptake is the early step in artery-clogging foam-cell formation). The proposed mechanism involves modulation of PPAR signaling (peroxisome proliferator-activated receptors, master switches for fat and inflammation control). The evidence basis is a single well-conducted mouse study; results have not been replicated in humans. **Magnitude:** Significant reduction in aortic lesion size and plasma lipids in mice; exact percentage not generalizable to humans. #### Anti-Inflammatory and Immune-Modulating Effects Across autoimmune-disease models, including experimental autoimmune encephalomyelitis (a mouse model of multiple sclerosis), 3HAA dampens harmful immune activation; in aging worms it improves immune function and acts against gram-negative bacteria. The proposed mechanism includes induction of heme oxygenase-1 (a protective, anti-inflammatory enzyme) and broad modulation of immune-cell signaling. The evidence basis is multiple animal and cell-culture studies; human immune data are limited to observational metabolite measurements. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Protection Against Neurodegeneration In worms engineered to express amyloid-beta or polyglutamine (mimicking Alzheimer's and Huntington's disease), raising 3HAA delayed age-associated paralysis, an effect that occurred even without reduced protein aggregation; 3HAA is also predicted to bind amyloid-beta and reduce its clumping in test-tube experiments. The basis is mechanistic and limited to invertebrate models and in-vitro prediction, with no controlled mammalian or human studies, so this benefit remains hypothetical for people. #### Mediation of Exercise Benefits In middle-aged adults, six months of endurance exercise raised blood 3HAA by 85–134%, and 3HAA levels track inversely with measures associated with aging, raising the possibility that 3HAA is one chemical signal carrying some longevity benefits of physical activity. This is an association from a small human study rather than evidence that supplemental 3HAA reproduces exercise benefits; the causal link is unproven and the idea is speculative. ## Benefit-Modifying Factors * **Genetic variation in pathway enzymes:** Activity of HAAO and upstream enzymes (KYNU, kynureninase, which produces 3HAA; and KMO, kynurenine 3-monooxygenase, which routes tryptophan toward 3HAA's precursor) varies between individuals and could determine baseline 3HAA levels and how much accumulates; those with naturally lower HAAO activity might already sit at higher 3HAA and respond differently. * **Baseline biomarker levels:** People with already-high oxidative stress, inflammation, or a high kynurenine-to-tryptophan ratio may have a different response than those with low baseline values, since the proposed mechanism is a hormetic (stress-response) one that depends on starting conditions. * **Sex-based differences:** The pilot mouse longevity data were strongest in female HAAO-knockout mice, while the dietary-supplementation lifespan effect was reported in aging males, suggesting sex may modify which delivery route or outcome is most affected; the basis is preliminary. * **Pre-existing health conditions:** Cardiovascular disease, autoimmune conditions, and neurodegenerative disease are the contexts where animal benefits appeared, so individuals with these conditions are the ones in whom benefits have been modeled — though only in animals. * **Age:** Benefits in animals were specifically tied to aging — effects on healthspan, immune function, and proteotoxicity appeared in older animals, suggesting older adults at the upper end of the target range may be the most relevant population, while effects in the young are untested. ## Potential Risks & Side Effects A dedicated search of toxicology, pharmacology, and primary literature was performed for the risk profile below. ### High 🟥 🟥 🟥 (No risks qualify for the High evidence level. There are no human safety trials of 3HAA, so no risk is supported by high-quality human evidence.) ### Medium 🟥 🟥 (No risks qualify for the Medium evidence level.) ### Low 🟥 #### Pro-Oxidant Toxicity in the Presence of Metals In cell-culture studies, 3HAA generates superoxide and hydrogen peroxide and enhances copper-induced toxicity in brain astrocytes, reducing cell viability and mitochondrial function. The proposed mechanism is metal-catalyzed redox cycling, in which 3HAA reduces copper or iron and drives production of damaging reactive oxygen species. The evidence basis is rat astrocyte and biochemical studies; relevance to whole-body human supplementation at physiological doses is unknown, and the same redox chemistry underlies its proposed benefits, making context critical. **Magnitude:** Not quantified in available studies. #### Conversion Toward Quinolinic Acid 3HAA sits one enzymatic step upstream of quinolinic acid, an excitotoxin implicated in neurodegeneration and neuroinflammation. Supplying extra 3HAA could in principle increase flux toward quinolinic acid, though raising 3HAA specifically by blocking its breakdown would instead reduce downstream quinolinic acid. The evidence basis is pathway biochemistry rather than direct toxicity studies of 3HAA supplementation; the net effect on quinolinic acid in humans is unestablished. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Unknown Effects of Chronic Human Supplementation No human has been studied taking 3HAA as a chronic supplement, so the entire long-term safety profile — including effects on liver, kidney, immune tolerance, and cancer-relevant immune signaling — is unknown. Because the kynurenine pathway also participates in immune suppression and tumor immune evasion, shifting pathway metabolites chronically carries theoretical, unquantified risk. This concern rests on mechanistic reasoning and the absence of data rather than on observed harm. #### Disruption of Immune Balance Kynurenine pathway metabolites help regulate immune tolerance, and 3HAA can induce apoptosis (programmed cell death) in certain immune cells under pathophysiological conditions. Chronically altering 3HAA might therefore shift immune function in unintended directions, for example over-suppressing or over-activating immune responses. This is an isolated-report and mechanistic concern with no controlled human data. ## Risk-Modifying Factors * **Genetic variation in pathway and metal-handling genes:** Variants in the kynurenine pathway enzymes (HAAO, KYNU, KMO) could set how much 3HAA accumulates and therefore how much pro-oxidant load a given exposure produces, while variants in iron- and copper-handling genes (HFE, linked to hereditary hemochromatosis; ATP7B, linked to Wilson's disease) raise tissue metal levels and could amplify 3HAA's metal-catalyzed toxicity; none of this has been tested directly for 3HAA risk. * **Metal status (copper and iron):** Because 3HAA's toxic redox chemistry is metal-catalyzed, individuals with copper or iron overload (e.g., hemochromatosis or Wilson's disease) could plausibly be at higher risk of pro-oxidant harm; those with normal metal status may face less of this specific concern. * **Baseline oxidative stress and antioxidant capacity:** People with depleted glutathione or impaired NRF2 signaling might tolerate the pro-oxidant aspect of 3HAA poorly, whereas robust antioxidant defenses could buffer it. * **Sex-based differences:** Animal data hint that sex modifies kynurenine pathway handling, but no sex-specific human risk data exist; this remains an open question rather than a documented difference in side effects. * **Pre-existing neurological or autoimmune conditions:** Those with neurodegenerative disease or active autoimmunity sit closest to the pathways 3HAA influences, and could in principle experience either benefit or harm; the direction is unestablished. * **Age:** Older adults, the primary target population, generally have higher baseline kynurenine pathway activity and oxidative burden, which could amplify either the protective or the harmful arm of 3HAA's action; this is inferred, not measured. ## Key Interactions & Contraindications * **Prescription drug interactions:** No human interaction studies exist. Theoretical caution applies with drugs that affect the kynurenine pathway or metal handling, including IDO/TDO-modulating agents used in oncology (the enzymes that open the pathway) and copper-chelating drugs such as penicillamine and trientine; the consequence would be unpredictable shifts in pathway metabolites. * **Over-the-counter medication interactions:** No documented interactions. High-dose iron or copper supplements are a theoretical concern because 3HAA's pro-oxidant toxicity is metal-catalyzed; combining them could in principle increase reactive-oxygen-species generation. Caution and separation are reasonable. * **Supplement interactions:** No documented interactions. Antioxidant supplements (e.g., N-acetylcysteine, vitamin C) could theoretically blunt the hormetic, NRF2-activating mechanism thought to drive 3HAA's benefits, while metal-containing supplements could amplify its pro-oxidant risk. * **Additive effects:** Other NRF2-activating compounds (e.g., sulforaphane from broccoli sprouts, curcumin from *Curcuma longa*) could have additive effects on the same antioxidant-response pathway 3HAA is proposed to engage, with unknown combined consequences. * **Other intervention interactions:** Endurance exercise itself raises 3HAA, so combining supplementation with intensive training would stack two inputs to the same metabolite, with effects that have not been studied. * **Populations who should avoid it:** Pregnant or breastfeeding individuals, children, people with copper or iron overload disorders, and anyone with active cancer or significant neurodegenerative or autoimmune disease should avoid 3HAA, given the complete absence of human safety data and the pathway's involvement in immune regulation. * **Severity and consequence:** All interactions above are classified as caution-level and theoretical, because no clinical interaction has been observed; the potential clinical consequence is increased oxidative damage or unpredictable immune modulation. * **Specific thresholds:** Because no human dosing or toxicity thresholds exist, the only defensible classifications are categorical — avoid entirely in the populations listed above and in anyone with diagnosed iron-overload (e.g., ferritin and transferrin saturation in the hemochromatosis range) or copper-overload conditions. ## Risk Mitigation Strategies * **Separation from metal supplements:** Because 3HAA's pro-oxidant toxicity is copper- and iron-catalyzed, the relevant mitigation is non-coadministration with high-dose iron or copper supplements; separating any unavoidable metal intake by several hours reduces metal-driven reactive-oxygen-species generation. * **Baseline metal-status screening:** Measuring baseline ferritin, transferrin saturation, and copper before any exposure identifies individuals with undiagnosed iron or copper overload, the group at greatest theoretical risk of pro-oxidant harm. * **Lowest conceivable exposure:** With no established human dose, the mitigation favored in the literature is the smallest amount and infrequent use, since the hormetic mechanism implies that modest, not maximal, exposure is what may benefit cells — reducing the risk of tipping 3HAA from protective into toxic, pro-oxidant territory. * **Exercise as an alternative lever:** Endurance training raised blood 3HAA by 85–134% over six months with an established safety record, offering a way to elevate the metabolite that sidesteps the unknown risks of unstudied oral supplementation. * **Exclusion of vulnerable populations:** Excluding pregnant or breastfeeding people, children, and those with cancer, active autoimmunity, or neurodegenerative disease limits exposure in groups where the kynurenine pathway's role in immune and neural regulation makes unintended harm most plausible. * **Symptom surveillance:** Because of the theoretical link to quinolinic-acid excitotoxicity, surveillance for new neurological symptoms (headache, cognitive changes), with discontinuation if they arise, addresses the risk of unrecognized downstream toxicity. ## Therapeutic Protocol There is no validated human therapeutic protocol for 3HAA. The points below describe what is and is not known, framed for readers evaluating a frontier intervention. * **Standard protocol used by practitioners:** None exists. 3HAA is not an established clinical or supplement intervention; no leading practitioner or clinic publishes a 3HAA dosing protocol, because human use has not been studied. * **Competing approaches:** Two conceptual routes to raising 3HAA are discussed in the research literature without either being framed as standard — direct dietary supplementation of 3HAA (used in aging mice) versus inhibiting the HAAO enzyme so endogenous 3HAA accumulates (modeled genetically in worms and mice). A third, indirect route is endurance exercise, which raises 3HAA naturally in humans. * **Expert or clinic that popularized each approach:** The lifespan-extension and dietary-supplementation work was led by the Sutphin laboratory (University of Arizona) in collaboration with The Jackson Laboratory; the human exercise findings come from the Zimmer/Joisten groups at TU Dortmund and the University of Göttingen. No clinic offers 3HAA therapeutically. * **Best time of day:** Unknown; no chronobiology data exist for 3HAA dosing. * **Expected half-life:** As the substrate of HAAO, free 3HAA is cleared within seconds to minutes, which is a central practical obstacle — orally supplied 3HAA would be rapidly metabolized, a key reason researchers have explored HAAO inhibition rather than supplementation alone. * **Single versus split dosing:** Undetermined. The very short half-life implies that any sustained elevation would require either continuous delivery or enzyme inhibition rather than a single oral dose, but no human dosing schedule has been tested. * **Genetic polymorphisms:** Variants in HAAO, KYNU, and KMO could influence baseline 3HAA and the response to any intervention, but no pharmacogenetic dosing guidance exists. * **Sex-based differences:** Pilot mouse data suggested sex influenced which route produced longevity effects (HAAO knockout in females, dietary 3HAA in aging males), but this has not been translated into human dosing guidance. * **Age-related considerations:** Animal benefits were concentrated in older animals, so older adults are the population in whom any future protocol would most plausibly be aimed; no age-specific human dosing is established. * **Baseline biomarker levels:** Baseline oxidative-stress markers and kynurenine-to-tryptophan ratio could in theory guide who might respond, but no biomarker-guided protocol has been validated. * **Pre-existing health conditions:** The cardiovascular, autoimmune, and neurodegenerative contexts where animal benefits appeared would shape any future indication, but no condition-specific human protocol exists. ## Discontinuation & Cycling * **Lifelong versus short-term use:** Undetermined. Animal benefits derived from chronic elevation (genetic knockout or continuous dietary supplementation), suggesting sustained exposure may be required for longevity effects, but no human data define an appropriate duration. * **Withdrawal effects:** None are known or expected; 3HAA is a normal endogenous metabolite that the body continuously produces and clears, so stopping supplementation would simply return levels toward baseline. No withdrawal syndrome has been described. * **Tapering protocol:** Not applicable; given rapid clearance and the absence of dependence, no taper would be physiologically necessary. This is inferred from its short half-life rather than from human studies. * **Cycling:** Whether cycling preserves any hormetic benefit is unstudied. Because the proposed mechanism is a stress-response that could theoretically adapt with constant exposure, intermittent use is a reasonable hypothesis, but there is no evidence to recommend a specific cycling pattern. ## Sourcing and Quality * **Source and form:** 3HAA is available only as a research-grade laboratory chemical (e.g., from chemical-reagent suppliers), not as a regulated dietary supplement manufactured for human consumption; this is the central sourcing limitation and a strong reason for caution. * **What to look for:** Because no human-grade product exists, there is no third-party-tested consumer supplement to evaluate; research chemicals carry purity certificates (e.g., ≥98% by HPLC, high-performance liquid chromatography, a standard lab method for measuring purity) intended for laboratory use, not assurances of safety or suitability for ingestion. * **Purity and contamination concerns:** Research-grade material may contain residual solvents, heavy metals, or synthesis byproducts not screened to food-supplement standards; the metal-contamination concern is amplified by 3HAA's metal-catalyzed pro-oxidant chemistry. * **Reputable brands or compounding pharmacies:** No reputable supplement brand or compounding pharmacy is known to produce 3HAA for human use; the absence of a legitimate consumer supply chain is itself a key finding of this section. ## Practical Considerations * **Time to effect:** Unknown in humans. In animals, longevity and healthspan effects were measured over the lifespan, and atherosclerosis benefits appeared over eight weeks of treatment in mice; no human time-to-benefit has been established. * **Common pitfalls:** The most common conceptual error is treating 3HAA as a ready-to-use longevity supplement — it is an early-stage research metabolite with no human dosing, rapid breakdown in the body, and no consumer-grade product. Another pitfall is assuming "more is better," when the proposed mechanism is hormetic and excessive amounts may be pro-oxidant or toxic. * **Regulatory status:** 3HAA is not approved or regulated as a drug or dietary supplement for human use by the FDA or comparable agencies; it exists in a regulatory gap as a research chemical, and any human use is entirely off-label and unsanctioned. * **Cost and accessibility:** As a research reagent, 3HAA is relatively inexpensive per gram but is not sold through normal supplement channels; accessibility for legitimate, safe human use is effectively nil, which is the dominant practical barrier rather than cost. ## Interaction with Foundational Habits * **Sleep:** Indirect interaction. The kynurenine pathway connects to serotonin and melatonin metabolism through shared tryptophan precursor, so shifting tryptophan toward the kynurenine branch could in theory affect sleep-related metabolites; no direct evidence shows 3HAA itself improves or disrupts sleep, so the practical effect is unknown. * **Nutrition:** Direct interaction. 3HAA is made from dietary tryptophan, so protein and tryptophan intake set the raw material for the whole pathway; additionally, dietary copper and iron are practically important because they catalyze 3HAA's pro-oxidant chemistry, making it sensible to avoid taking 3HAA alongside high-metal meals or supplements. * **Exercise:** Direct, potentiating interaction. Endurance exercise raised blood 3HAA by 85–134% over six months in middle-aged adults, meaning exercise and 3HAA push the same metabolite in the same direction; this makes exercise both a natural way to raise 3HAA and a confounder for anyone trying to attribute effects to supplementation. Timing relative to any dosing is unstudied. * **Stress management:** Indirect interaction. Psychological stress and inflammation activate the kynurenine pathway (via cortisol and immune signaling), which can raise pathway metabolites including 3HAA; whether managing stress meaningfully changes 3HAA levels or its effects is not established, so the proposed mechanism is plausible but unproven. ## Monitoring Protocol & Defining Success Because 3HAA has no validated human use, the monitoring framework below is precautionary, aimed at detecting harm and tracking the biological systems 3HAA is proposed to influence rather than confirming an approved therapeutic effect. Before any experimental use, baseline testing should establish metal status and the markers of oxidative stress and inflammation that the kynurenine pathway influences, so that any change can be interpreted and so that contraindicated individuals (iron or copper overload) are identified. Ongoing monitoring, if used at all, should occur at baseline, at roughly 4–8 weeks, and then every 3–6 months, with prompt re-checking if any new symptom arises. * **Baseline labs:** ferritin, transferrin saturation, serum copper/ceruloplasmin, high-sensitivity CRP (C-reactive protein), complete blood count, and comprehensive metabolic panel. * **Ongoing labs:** repeat the inflammatory and metal markers and liver and kidney function on the cadence above. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Ferritin | 30–150 ng/mL (women), 50–200 ng/mL (men) | Screens for iron overload that amplifies 3HAA pro-oxidant risk | Acute-phase reactant; pair with transferrin saturation; conventional upper limit (~300–400) is far higher than the functional ceiling | | Transferrin saturation | 20–40% | Detects iron overload (hemochromatosis) before symptoms | Fasting morning draw preferred; >45% warrants avoidance of 3HAA | | Serum copper / ceruloplasmin | Copper 70–140 µg/dL | Identifies copper excess that catalyzes 3HAA toxicity | Interpret together; supplement metals separately from any 3HAA | | hs-CRP (high-sensitivity C-reactive protein) | <1.0 mg/L | Tracks systemic inflammation 3HAA is proposed to lower | Avoid testing during acute illness; fasting not required | | ALT/AST | <25 U/L | Surveillance for unstudied hepatic effects | Liver enzymes; conventional reference upper limit (~40) is higher than the optimal functional ceiling | | eGFR | >90 mL/min/1.73m² | Surveillance for unstudied renal effects | Estimated glomerular filtration rate, a measure of kidney function; affected by hydration and recent high protein intake | * **Qualitative markers:** - Energy and vitality through the day - Cognitive clarity and absence of new neurological symptoms (a precaution against theoretical quinolinic-acid effects) - Sleep quality - Exercise recovery and tolerance Defining success is necessarily provisional: in the absence of approved endpoints, "success" would mean stable or improved inflammatory and metabolic markers, no deterioration in liver, kidney, or neurological status, and subjective wellbeing — not any proven extension of human lifespan, which current evidence cannot demonstrate. ## Emerging Research Research on 3HAA is at an early, rapidly evolving stage, and the items below reflect studies and directions that could strengthen or weaken the case for it. * **No interventional human trials registered:** A search of ClinicalTrials.gov found no registered trials testing 3HAA supplementation or HAAO inhibition as an intervention in humans; current human-facing studies measure kynurenine pathway metabolites observationally rather than dosing 3HAA. This absence is itself a key finding and a barrier to translation. * **Translation of the longevity mechanism to mammals:** The pivotal report by [Dang et al., 2023](https://pubmed.ncbi.nlm.nih.gov/38097593/) established the worm lifespan effect and pilot mouse data; the central future question is whether adequately powered mammalian lifespan studies confirm the effect — a result that could substantially strengthen the case. The same work could weaken it if larger mouse cohorts fail to replicate the pilot findings. * **Neurodegeneration models:** [Hull et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38786006/) showed 3HAA delays proteotoxic paralysis in worm Alzheimer's and Huntington's models; future research extending this to mammalian neurodegeneration models will determine whether the protective signal survives in more complex nervous systems, and the pro-oxidant/quinolinic-acid literature provides the counter-hypothesis that it may not. * **Immune and aging biology:** A bioRxiv preprint by [Espejo et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38260592/) (not yet peer-reviewed) reported that 3HAA improves aging immune function and has antimicrobial activity in worms via tissue compartmentalization; whether an analogous, evolutionarily conserved immune role exists in mammals is an open area that could cut either way given the pathway's dual role in immune tolerance and tumor immune evasion. * **Exercise as a natural lever:** [Joisten et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40178293/) demonstrated that endurance training raises human 3HAA by 85–134%, opening the question of whether 3HAA mediates measurable longevity benefits of exercise; confirming a causal mediating role would strengthen interest, while finding it is merely a passive marker would weaken the supplementation rationale. * **Enzyme-targeting drug development:** Reviews such as [Pocivavsek et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39304346/) highlight HAAO and other kynurenine pathway enzymes as emerging pharmacological targets; future selective HAAO inhibitors could test the "raise endogenous 3HAA" hypothesis more cleanly than supplementation, and their safety profiles will be decisive. ## Conclusion 3HAA is a small molecule the body naturally makes when it breaks down a dietary protein building block. Long dismissed as a throwaway step, it has drawn fresh attention because raising its levels made laboratory worms and mice live longer and stay healthier, and because the same molecule rises in people's blood after months of regular exercise. The most striking proposed action is that 3HAA switches on the body's built-in defenses against cellular damage, while also directly mopping up a harmful reactive chemical. The evidence, however, is early and mixed. Every claim of benefit — longer life, healthier arteries, calmer inflammation, protection of nerve cells — rests on animal, cell, or test-tube work, with no human trials of 3HAA as a supplement. At the same time, the very chemistry behind its benefits can turn harmful in the presence of certain metals, and it sits just upstream of a nerve-damaging compound, so its overall effect appears to depend heavily on dose and circumstance and is genuinely debated. Practically, 3HAA is broken down within seconds in the body, exists only as a research chemical rather than a tested supplement, and has no human dosing or safety record. It is best understood today as a promising but unproven research metabolite, with raising it through exercise being the one approach backed by human data. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**